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Abstract
Checkpoint kinase 1 (Chk1) is a checkpoint gene that is
activated after DNA damage. It phosphorylates and
inactivates the Cdc2 activating phosphatase Cdc25C.
This in turn inactivates Cdc2, which leads to G2/M
arrest. We report that blocking Chk1 expression by
antisense or ribozymes in mammalian cells induces
apoptosis and interferes with the G2/M arrest induced
by adriamycin. The Chk1 inhibitor UCN-01 also blocks
the G2 arrest after DNA damage and renders cells more
susceptible to adriamycin. These results indicate that
Chk1 is an essential gene for the checkpoint mechanism
during normal cell proliferation as well as in the DNA
damage response. Neoplasia (2001) 3, 411–419.
Keywords: Chk1, antisense, ribozyme, checkpoint, chemotherapy sensitization.
Introduction
Checkpoint kinase 1 (Chk1), initially identified in Schizo-
saccharomyces pombe [1 ], is a G2/M checkpoint gene that
is conserved throughout the eukaryotic kingdom. Checkpoint
genes are activated after DNA damage. The sensors of DNA
damage send out two signals. The first signal activates
checkpoint pathways that halt the cell cycle in either G1 or
G2. The second signal leads to the activation of DNA repair
[2 ].
In S. pombe or mammalian cells the cyclin B-Cdc2 kinase
complex controls cell cycle progression through the G2/M
boundary. Cdc2 is inactivated through phosphorylation at
Tyr -15 by either Wee1 or Myt1. The phosphatases Cdc25
(S. pombe ) or Cdc25C (mammalian) can remove the
inhibitory phosphate from Tyr-15 on Cdc2 and permit cell
cycle progression [3–8].
The function of Chk1 has been studied in both S. pombe
and mammalian cells and found to be roughly analogous.
In S. pombe, after DNA damage, Chk1 induces cell cycle
arrest but is not involved in the activation of DNA repair.
The chk1 strain of S. pombe is viable under normal
conditions but is not viable when DNA is damaged. This
strain is also defective in delaying mitosis following  -
irradiation in a wee1-50/mik1 background (Mik1 phos-
phorylate Cdc2 at Tyr-15 and inactivates it in S. pombe )
[9 ]. S. pombe Chk1 is phosphorylated in a Rad3-depend-
ent manner shortly after DNA damage [10]. Active Chk1
phosphorylates Cdc25, which provides a binding site for the
14-3-3 family protein Rad24. Once bound by Rad24,
Cdc25 is exported out of the nucleus [11]. However, the
nuclear exclusion of Cdc25 is not required for the DNA
damage response and direct inhibition of Cdc25 phospha-
tase activity by Chk1 may be sufficient for the cell cycle
arrest [12,13]. As a result, Cdc2 is kept inactive by Wee1
and cells are arrested in G2. Chk1 has also been shown to
phosphorylate Wee1 in vitro, implying that Chk1 may also
facilitate G2 arrest through Wee1 [14,15].
An analogous checkpoint pathway involving ATM/ATR,
Chk1, and Cdc25C has been identified in mammalian cells
[16–18]. In Xenopus, ATR is required for Chk1 phosphor-
ylation in the SQ/TQ motifs. This phosphorylation is required
for DNA damage response [19]. After DNA damage, human
Chk1 phosphorylates Cdc25C at Ser-216. As a result, Cdc2
is not activated and cells are arrested at G2. Hypersensitivity
to radiotherapy is observed in ataxia telangiectasia patients
(ATM deficient ). Cells from these patients (A-T cells ) are
also hypersensitive to  - irradiation in vitro. Expression of S.
pombe Chk1 in A-T cells complements the defects in the G2
DNA damage checkpoint and improves the survival rate of
these cells after  - irradiation [20]. Recently, Chk1 has been
reported to stabilize Cdc25A and p53 during the DNA
damage response [21,22]. Therefore, Chk1 could also
reinforce the G1 checkpoint.
A second mechanism, distinct from Chk1, which can
phosphorylate Cdc25/Cdc25C has been identified in yeast
and mammals. The S. pombe Cds1/S. cerevisiae Rad53/
human Chk2 play roles similar to Chk1 downstream of
MEC1/Rad3/ATM in G2 checkpoint control. [23–25].
Cdc25C can also be phosphorylated by c-TAK1, the
physiological function of which is not known [26].
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Cdc25C phosphorylation at serine 216 is tightly regulated
and controls the timing of mitosis during the normal cell
cycle. During interphase, Cdc25C is phosphorylated, bound
by 14-3-3 proteins, and exported out of the nucleus. In
mitosis, dephosphorylated Cdc25C remains in the nucleus
where it activates Cdc2.
Recent reports have shown that CHK1 / mouse
embryos or ES cells exhibit a defect in the G2 checkpoint
mechanism. [18,27]. In this report, we blocked Chk1
expression and examined the phenotype in human cell
tumor cell lines. We used several approaches including full -
length antisense cDNA, ribozymes, and antisense oligonu-
cleotides to block Chk1 expression. Full - length Chk1
antisense and one of the ribozymes were the most effective
in blocking Chk1 expression in human cell lines. Cells with
reduced levels of Chk1 were found to be more prone to
apoptosis. Furthermore, when treated with DNA-damaging
agents such as adriamycin or etoposide, cells harboring low
levels of Chk1 protein exhibited defects in the G2/M
checkpoint. We also observed an additive cell -killing effect
when treating cells with Chk1 antisense/ ribozyme together
with adriamycin. In addition, we showed that potent Chk1
inhibitor UCN01 was able to override the adriamycin-
induced G2 arrest. Furthermore, we found that UCN01
sensitized the human lung carcinoma cell line H1299 to
adriamycin.
Materials and Methods
Ribozyme Design and Plasmid Construction
Ribozymes are enzymatic RNA molecules that cleave the
targeted mRNA [28]. The Chk1 mRNA secondary structure
was analyzed using the MFold program/GCG software
[Wisconsin Package Version 10.0, Genetics Computer
Group (GCG), Madison, WI]. Ribozymes were designed to
hybridize to the putative single-stranded regions. The
sequences of these ribozymes are: ribo910: AG-
CTTCTTCTCCActgatgaggccgaaaggccgaaaGGCACCTTT;
ribo1112: AGCTTTCTTCAGTctgatgaggccgaaaggccgaaa-
CTCTATTCT; ribo1314: AGCTTATCCCTGTctgatgaggcc-
gaaaggccgaaaGTTATTCCT; ribo1516: AGCTTCTGAGAT-
TTTctgatgaggccgaaaggccgaaaGGTTATCCT. The upper-
case letters represent the regions that hybridize to the
Chk1 coding region. The lowercase letters represent the
ribozyme catalytic sequence. The ribozymes, full - length
Chk1 sense cDNA and antisense cDNA were cloned into a
pCMV vector between HindIII and XbaI sites. Clones were
confirmed by sequencing.
Cell Lines, Chemicals and Reagents
NCI-H1299, HCT116, and Hela cells were obtained from
ATCC. UCN-01 was obtained from the Synthetic Chemistry
Department at the National Cancer Institute, Bethesda, MD.
Nocodazole was purchased from Calbiochem, San Diego,
CA. Unless otherwise stated all other chemicals were
purchased from Sigma. The following rabbit polyclonal
antibodies were purchased from Santa Cruz (La Jolla, CA):
Chk1 (C-16; Cat#: sc-7234); actin ( I -19; Cat#: sc-1616).
Transient Transfection
H1299 cells were grown at 378C in a 5% CO2 atmosphere
in RPMI 1640 supplemented with 10% fetal bovine serum, 1
mM sodium pyruvate, 1 mMHepes, 1 mM glutamine, and 4 g
l1 glucose. Transfection with LipofectAMINE PLUS DNA
(1.5 g ml1 ) was mixed with LipofectAMINE PLUS (Life
Technology, Rockville, MA, Cat#: 10964-013) for 15minutes
at room temperature. This mixture was then mixed with
LipofectAMINE reagent and incubated for 15minutes at room
temperature to form DNA complexes. The DNA complexes
were added to cells in RPMI media without serum. After a 4-
hour incubation at 378C, the transfection mixture was
replaced with normal growth media. Transfection with
LipofectAMINE 2000. The appropriate DNA (1.5 g ml1
unless otherwise specified) was mixed with LipofectAMINE
2000 (Life Technology, Cat#: 11668-027) for 15 minutes at
room temperature to form DNA complexes. The DNA
complexes were added to each tissue-culture plate with
the complete media. After a 6-hour incubation at 378C, the
transfection mixture was replaced with normal growth media.
Western Blotting
Cells were lysed in lysis buffer [20 mM Tris–Cl, pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% Na
deoxycholate, 0.1% SDS, 1 mM DTT, 0.25 mM PMSF, 1
protease inhibitor cocktail (Boehringer Mannheim, Germany,
Cat# 1697498) ]. After brief sonication, insoluble debris were
pelleted (14,000 rpm, 30 minutes, 48C) and the protein
concentration of the resulting supernatant was determined
using the Bradford method. Total cell lysates (100 g
protein) were loaded onto SDS-gradient gel (Novex, San
Diego, CA), electrophoresed, and electrotransferred to 0.2 
nitrocellulose membranes (Novex). Antibody detecting was
carried out according to the manufacturer’s instructions
(Amersham Pharmacia Biotech, IL).
Apoptosis Assay
Both the floating and adherent cells were harvested,
washed, and resuspended in 1.0 ml of ice-cold phosphate-
buffered saline (PBS) containing 2 g ml1 40,6 -diamidino-
2-phenylindole (DAPI). The cells were rocked for 1 hour at
room temperature in the dark and then washed two times
with PBS after staining. The resuspended sample (15 l )
was dropped onto a glass slide, covered with a glass
coverslip and apoptotic cells were scored. For each sample,
at least 600 cells were randomly counted by fluorescence
microscopy and the percentage of apoptotic cells was
determined based on evidence of nuclear fragmentation
and abnormal chromosome condensation.
Alamar Blue Assay
Twenty- four hours after transfection, the transfected
cells were trypsinized and re-plated onto a 96-well tissue
culture dish at 7500 cells per well. Cells were allowed to
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grow in complete media at 378C for 48 hours. The cells
were then gently washed with 200 l of PBS. Alamar Blue
reagent (Biosource International, Camarillo, CA; Cat#:
DAL1100) was diluted 1/10 in normal growth media. The
diluted Alamar Blue reagent (100 l ) was added to each
well on the 96-well plate and incubated until the reaction
was complete as per manufacturer’s instructions. Analysis
was performed using an fmax Fluorescence Microplate
Reader (Molecular Devices, Sunnyvale, CA), set at the
excitation wavelength of 544 nm and emission wavelength
of 595 nm. Data was analyzed using SOFTmax PRO
software provided by the manufacturer.
Flow Cytometry
Cells were harvested, washed, and resuspended in 500 l
of ice-cold PBS. Five milliliters of 100% ethanol was added
to fix cells at 48C overnight. Cells were then washed once
with ice-cold PBS plus 0.1% bovine serum albumin (BSA)
and resuspended in 800 l of ice-cold PBS+0.1% BSA.
Resuspended cells were treated with RNase A (1 mg ml1)
and stained with propidium iodide (100 g ml1) for 30
minutes at 378C. Cell cycle analysis was performed using a
Becton-Dickinson (San Jose, CA) fluorescence-activated
cell analyzer. Data were analyzed using the ModFitLTmodel
provided by the manufacturer. Results represent a minimum
of 10,000 cells assayed for each sample.
Caspase Assay
H1299 cells were transfected with pCMV vector, Chk1
full - length antisense cDNA or ribo910. Twenty- four hours
after transfection, the cells were split onto 96-well plates at
7500 cells /well for additional 24-hour incubation. The cells
were lysed in 120 l of lysis buffer [16 mM Hepes–KOH, pH
7.5, 67 mM KCL, 8 mM MgCl2, 0.22 mM PMSF, 1.11 mM
DTT, 1.11 g ml1 pepstatin A, 1.1 g ml1 leupeptin, 5.56
g ml1 aprotonin, 0.11 mM EGTA, 0.11 mM EDTA, 0.56%
CHAPS (wt /vol ) ] for 20 minutes. ICE buffer (80 l ) was
mixed with the cell lysates and the fluorescence was
measured with a Cytofluor fluorometer (PerSeptive Biosys-
tems (Foster City, CA) excitation=360/40, emission=460/
40, gain=38, cycle=1) at 0 and 3 hours after incubation at
378C. Caspase activity was calculated as units per hour by
substracting the 0-hour reading from the 3-hour reading and
dividing by 3.
Mitotic Index
Twenty- four hours after transfection, H1299 cells were
treated for 8 hours with 300 ng ml1 adriamycin or 20 g
ml1 etoposide followed by an additional 16-hour incubation
together with 40 ng ml1 nocodazole (Calbiochem, San
Diego, CA; Cat#: 487928). Cells were harvested by
trypsinization, washed with PBS, centrifuged (1200 rpm, 3
minutes), and then resuspended in 0.5 ml of hypotonic buffer
containing 75 mM KCl. Cells were centrifuged immediately
(1200 rpm, 3 minutes) and again resuspended in 100 l of
hypotonic buffer. Samples were dropped onto glass slides,
air -dried, and stained with the Diff -Qwik Stain Set (Dade,
Deerfield, IL; Cat#: B4132-1) according to the vendor’s
instructions. For each sample, at least 600 cells were
randomly counted by light microscopy and mitotic cells were
scored based on evidence of mitotic chromosomal con-
densation and the lack of a nuclear membrane.
Results
Chk1 is Required for the Checkpoint Mechanism During the
Normal Cell Cycle
We examined the Chk1 expression profile during the cell
cycle progression. H1299 cells were treated with mevastatin
for 24 hours to achieve G1 synchronization. Cells were
released from the mevastatin arrest and harvested at
different time points. The Chk1 protein level was analyzed
using Western blotting techniques and the cell cycle
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Figure 1. Chk1 expression during the cell cycle. Cells were harvested 0, 6, 13,
17, 20, 24, 27, 30, and 33 hours post mevastatin release and subjected to flow
cytometry and western blot analysis as described. (A) FACS analysis. (B) The
quantification of the FACS analysis. (C) Western blot of total cell lysates with
Chk1 antibody or actin antibody. (D) Western blot of baculovirus - expressed
recombinant Chk1 and total cell lysate from NCI -H1299, Hela and HCT116
cells.
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distribution was examined using fluorescence-activated cell
sorting analysis (FACS). The Chk1 antibody recognizes the
recombinant Chk1 expressed in baculovirus, which comi-
grates with the recognized antigen in the total cell lysates
(Figure 1D ). The majority of cells progressed into the S
phase within 20 to 24 hours of mevastatin release. Chk1
protein levels were low during G1 and elevated during S and
later (Figure 1A C ). The same cell cycle–dependent Chk1
expression pattern was seen in H1299 cells synchronized by
contact inhibition (data not shown). The Chk1 level is high
when the cells are arrested in G1 by either mevastatin
(Figure 1 ) or contact inhibition (data not shown), suggesting
that Chk1 could be upregulated in response to G1 arrest
induced by these treatments and downregulated at G1 during
normal cell cycling. In contrast to our findings, Kaneko et al.
[29] showed that Chk1 was downregulated when the cells
were in quiescence after serum starvation. This difference
could be due to different treatments or differences in cell lines
unique to each experimental condition. These results
suggest a function for Chk1 in the S or the G2/M phases of
the cell cycle. Indeed, it has been reported that Chk1 kinase
activity is upregulated during the S and the G2/M phases
[29]. To study Chk1 function, we used several approaches to
block Chk1 expression in mammalian cells. We transfected
vectors that expressed full - length sense or antisense Chk1
cDNA, antisense oligonucleotides, or ribozymes (Figure 2A )
in H1299 cells using LipofectAMINE PLUS. Approximately
80% of the cells were transfected as judged by cotransfection
with a green florescent protein expression vector (data not
shown). Total RNA was extracted and real - time quantitative
RT-PCR was used to measure the Chk1 mRNA level in the
adherent cells. Full - length Chk1 sense and antisense cDNAs
were expressed at 700- to 900- fold over the endogenous
Chk1 mRNA level (data not shown).
Figure 2. Blocking Chk1 expression induces cell death. (A) Cartoon of human Chk1 gene and the hybridization positions for different ribozymes. (B) Chk1 protein
levels in the transfected cells. H1299 cells were transfected with different plasmids as indicated below using LipofectAMINE PLUS. Western analysis of the total cell
lysates was performed as described. The filter was blotted with anti -Chk1 antibody ( top panel ) followed by blotting with anti - actin antibody ( lower panel ). Lane 1:
vector control; lane 2: full - length Chk1 sense cDNA; lane 3: full - length Chk1 antisense cDNA; lane 4: ribozyme 910; lane 5: ribozyme 1112; lane 6; ribozyme 1314;
lane 7: ribozyme 1516. (C) Blocking Chk1 expression induces cell death. Cells were harvested 24 hours after transfection. The apoptosis assay was carried out as
described. (D) Blocking Chk1 expression decreases cell survival. H1299 cells were transfected with different plasmids as indicated. An Alamar Blue assay was
carried out to determine the cell survival.
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In order to be able to observe a decrease in Chk1 protein
levels in transient transfection experiments, Chk1 must have
a relatively short half - life. We measured the half - life of Chk1
to be 3 to 5 hours (data not shown). Western analysis
revealed that the expression of Chk1 sense cDNA resulted in
a two- fold increase in Chk1 protein levels (Figure 2B ). The
full - length Chk1 antisense cDNA reduced the Chk1 protein
level to 30% to 50% of that of the empty vector control.
Ribozyme 910 (ribo910) was as effective as full - length
Chk1 antisense cDNA in reducing Chk1 expression. Ribo-
zymes 1112 and 1314 had intermediate blocking effects
(Figure 2B ). We also transfected Chk1 antisense oligonu-
cleotides into H1299 cells. We found that four of the 14 Chk1
antisense oligonucleotides were effective in reducing Chk1
expression (data not shown).
S. pombe cells with the chk1 allele are viable [9]. In
contrast, we observed apoptosis in H1299 cells following
antisense or ribo910 treatment. The extent of cell death
correlates inversely with the Chk1 protein levels: full - length
Chk1 antisense cDNA and ribo910 were the most effective in
reducing Chk1 protein levels and they were also the most
potent in inducing apoptosis. Ribozyme 1112 and 1314 had
intermediate effects in reducing Chk1 expression and the
extent of apoptosis was concomitantly intermediate. Ribo-
zyme 1516 did not reduce the Chk1 protein level and had no
effect on cell survival. Importantly, a two- fold overexpression
of Chk1 protein in Chk1 sense cDNA transfectants appeared
to moderately protect cells from apoptosis (Figure 2C ). A
direct correlation was observed between the Chk1 protein
levels and the amount of viable cells (Figure 2D ). Similar
results were obtained in Hela cells (data not shown). We
also observed similar effects at 48 hours posttransfection
after removal of the dead cells at 24 hours posttransfection
(data not shown).
The dramatic cell death induced in the LipofectAMINE
PLUS–transfected cells masked the effect of DNA-damag-
ing agents. Therefore, we used LipofectAMINE 2000 in the
following experiments. Although the reduction of Chk1
protein levels and the extent of apoptosis were less
pronounced using LipofectAMINE 2000 (compare Figures
3 and 6A to Figure 2 ), the milder condition allowed us to
better examine the effect of DNA damage. We first
characterized the apotosis induced by Chk1 antisense and
ribo910 transfection. FACS analysis demonstrated that the
antisense cDNA and ribo910–transfected cells had a
significantly higher distribution in apoptosis than the vec-
tor - transfected cells. Additionally, there is a significant
increase in caspase activity in the antisense cDNA and
ribo910 transfected cells, indicating that cells die through
apoptosis (Figure 3D ). Furthermore, we consistently
observed a moderate increase in the G2/M population of
Figure 3. Blocking Chk1 expression induces cell death. H1299 cells were
transfected with different plasmids as indicated using LipofectAMINE 2000.
(A) Chk1 protein levels in the transfected cells. Lane 1: vector control; lane 2:
full - length Chk1 sense cDNA; lane 3: full - length Chk1 antisense cDNA; lane
4: ribozyme 910. (B) FACS analysis of the transfected cells. H1299 cells were
transfected with different plasmids as indicated. Twenty - four hours after
transfection, both the floating and the attached cells were harvested and
subjected to FACS analysis. (C) The quantification of the FACS analysis. (D)
Caspase assay. H1299 cells were transfected with different plasmids as
indicated. Fourty - eight hours after transfection, caspase activity was measure
as described in the Materials and Methods section.
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Chk1 sense- transfected cells (Figure 3B and C ). This
suggests that Chk1 is involved in the regulation of the timing
of mitosis onset during the normal cell cycle. Active Chk1
keeps cells in check before they are ready for mitosis. As a
consequence of decreasing Chk1 protein level, cells may die
of premature mitosis.
We have shown that Chk1 expression is cell cycle–
dependent and that Chk1 antisense or ribo910 can induce
apoptosis. Taken together, these results indicate that Chk1
function is essential for normal cell cycle progression.
Chk1 is Required for the G2 Arrest after DNA Damage
We used adriamycin and etoposide to examine the DNA
damage response in Chk1 antisense cDNA or ribo910-
transfected cells. Adriamycin induces a G2 block in H1299
cells (Figure 5 ). We examined the effect of Chk1 antisense
and ribo910 on the G2 checkpoint mechanism. The trans-
fected cells were treated with 200 ng ml1 adriamycin 24
hours after transfection to induce a DNA damage response.
Eight hours after the addition of adriamycin, 40 ng ml1
nocodazole was added to trap in mitosis those cells that had
A
B
Figure 4. Blocking Chk1 expression allows cells to partially escape the G2 arrest induced by adriamycin or etoposide. The mitotic indices of the transfected cells
were measured as described. (A) Morphology of the transfected cells treated with drugs. Cells with the typical mitotic chromosomal spread and the disappearance of
nuclear membrane are marked with arrows. (B) The mitotic indices of the cells. The value of each data point is the average from two independent experiments.
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escaped the G2 arrest. The mitotic indices of cells that were
transfected with Chk1 antisense cDNA or ribozyme 910 were
much higher than those of cells transfected with either vector
control or Chk1 sense cDNA (Figure 4 ). This result indicates
that more antisense or ribozyme 910 transfectants pro-
gressed through the G2/M boundary without being arrested.
Thus, the decreased Chk1 protein level results in a defect in
G2 arrest after DNA damage. A similar result was obtained
when the cells were treated with another DNA-damaging
agent, etoposide (Figure 4 ).
UCN01 (7-hydroxy staurosporine) has been shown to
specifically inhibit Chk1 and abrogate G2 checkpoint. UCN-
01 also inhibits c-TAK1. However, the physiological function
of c-TAK1 in G2/M checkpoint is not clear [30]. Both UCN-
01 and staurosporine inhibit Chk1 with an IC50 of 4 to 10 nM
[30–33]. We looked at the effect of UCN-01 or staurospor-
ine on the G2 arrest induced by adriamycin. H1299 cells
were treated with 300 ng ml1 adriamycin for 8 hours before
40 ng ml1 nocodazole was added to trap the mitotic cells.
Cells treated with either adriamycin alone, or adriamycin plus
nocodazole had very low mitotic indices, presumably
because they were arrested in late G2 by adriamycin.
Figure 6. (A) Blocking Chk1 expression and adriamycin have an additive
effect in killing tumor cells. Twenty hours after transfection, the transfected
cells were treated with or without adriamycin for 48 hours. The cells were
harvested and subjected to the apoptosis assay. The percentage of apoptotic
cells is shown. Each value is the average of values from two independent
experiments. (B) UCN-01 or staurosporine sensitizes H1299 cells to
adriamycin. H1299 cells were treated with different amounts of adriamycin
in combination with UCN-01 or staurosporine as indicated in the figure.
Forty - four hours after the treatment, the cells were harvested and subjected
to the apoptosis assay. The percentage of apoptotic cells is plotted against the
concentration of adriamycin. Each value is the average from two independent
experiments.
Figure 5. Staurosporine or UCN-01 overrides the G2 arrest induced by
adriamycin. (A) FACS analysis. H1299 cells were treated with 300 ng ml 1
adriamycin for 24 hours with or without the following drugs: 1 nM
staurosporine, 3 nM staurosporine, or 200 nM UCN-01. (B) The quantification
of the FACS analysis. (C) H1299 cells were treated with 300 ng ml 1
adriamycin for 8 hours before the addition of 40 ng ml 1 nocodazole with or
without 5 nM staurosporine or 200 nM UCN-01. Mitotic indices were
measured as described. The percentage of mitotic cells is plotted. Each
value is the average from two independent experiments.
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UCN-01 (200 nM) or 5 nM staurosporine alone had no effect
on mitotic index. However, H1299 cells treated first with
adriamycin followed by treatment with staurosporine or
UCN-01 plus nocodazole, showed a significant increase in
the mitotic index. This result indicates that UCN-01 and
staurosporine can override the G2 arrest induced by
adriamycin (Figure 5C ).
The cell cycle distribution was analyzed using FACS.
H1299 cells were treated with 300 ng ml1 adriamycin for 24
hours with or without the following drugs: 1 nM staurospor-
ine, 3 nM staurosporine, or 200 nM UCN-01. Treatment with
adriamycin alone induced a G2 arrest in 80% of the cells.
However, we observed a significant decrease in the
percentage of G2 cells upon addition of UCN-01 or
staurosporine to adriamycin- treated cells. In addition, we
observed that the S-phase fraction increased, which
indicates that more cells were cycling as a result of UCN-
01 or staurosporine addition. UCN-01 or staurosporine
alone can induce G1 arrest [34,35]. In our experiment, the
S-phase fraction increased suggesting that the decrease in
G2 fraction was not due to G1 arrest caused by UCN-01 or
staurosporine. In fact, UCN-01/staurosporine treatment
was able to override the adriamycin- induced G2 arrest and
pushed more cells into active cycling (Figure 5A and B ).
These results are consistent with Chk1 function indicated by
the Chk1 antisense or ribo910 experiments.
Chk1 Is Required for Cell Survival after DNA Damage
In the event of DNA damage, cells are halted in either G1
or G2 to repair DNA. This is vital for maintaining genetic
fidelity as well as for the survival of the cells. Thus, it is
expected that abrogation of these checkpoint mechanisms
would decrease cell survival. We examined the apoptotic
rate of transfected cells upon treatment with adriamycin. We
found that treatment with 600 ng ml1 adriamycin killed
H1299 cells in addition to the killing effect of Chk1 antisense
cDNA or ribo910 (Figure 6A ).
We also examined the cell survival rate of cells treated
with adriamycin in the presence or absence of UCN-01 or
staurosporine. H1299 cells were treated with different
amounts of adriamycin in combination with UCN-01 or
staurosporine. Forty- four hours after the treatment, the cells
were harvested and subjected to the apoptosis assay. Both
UCN-01 and staurosporine increased the efficacy of
adriamycin against H1299 cells. The potentiation by staur-
osporine showed a dose–response effect (Figure 6B ).
Therefore, inhibition of Chk1 could sensitize tumor cells to
chemotherapeutic agents.
Discussion
We have shown that blocking Chk1 expression induces
apoptosis, abrogates G2 arrest after DNA damage, and
sensitizes cells to DNA-damaging agents. This is in agree-
ment with the recent reports showing thatCHK1 / mouse
embryos or ES cells also exhibit a defect in the G2
checkpoint mechanism [18,27]. These data provide genetic
evidence that Chk1 is essential for the G2 checkpoint
mechanism during normal cell cycle as well as for the DNA
damage response.
In our experiments, cells transfected with the full - length
Chk1 antisense or ribo910 partially abrogated the G2 arrest
induced by either adriamycin or etoposide. The incomplete
G2 abrogation could be explained by two factors: (1) the
presence of the untransfected cells; (2) G2 arrest is largely
dependent on Cdc25C activity and Cdc25C can be phos-
phorylated and inhibited by both Chk1 and Chk2. Chk2 could
compensate for the loss of Chk1 and induce G2 arrest after
DNA damage [23–25].
More than 50% of tumors have mutations in p53.
Furthermore, almost all have G1 checkpoint deficiencies
[36]. Cells deficient in p53 cannot undergo p53-dependent
apoptosis and are resistant to drugs that induce the p53-
dependent apoptosis. In fact, such resistance has been
reported in many p53 null or mutated human tumor cell lines
as well as in clinical samples [37–41]. We have shown that
Chk1 antisense or ribo910 induces apoptosis in H1299 cells
that are deficient in p53. Thus, Chk1 inhibitors could provide
a cytotoxic cancer therapeutic agent, especially for p53-
deficient tumors.
It has been shown that G2 abrogation can sensitize
p53-deficient cells to DNA-damaging cancer therapeutic
agents [33,42–44]. In the present report, we show that
decreasing the Chk1 protein level by using antisense or
ribo910 sensitizes H1299 cells to adriamycin. Thus, we
expect that an inhibitor of Chk1 should sensitize tumors to
DNA-damaging cancer therapies. In fact, UCN01 or
staurosporine sensitizes H1299 cells to adriamycin, pre-
sumably due to its G2 abrogation activity. Thus, Chk1
inhibition may provide a useful and specific approach for
the treatment of cancer.
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